AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04002024 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo: 1 fingertip unit to cover one side of the face twice a day
Study NCT04393844 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: turbo-ject PICC set
Description: The turbo-ject PICC set, which will be used in this study, is the set for peripherally inserted central catheterization. In this study, we will see the difference according to the presence or absence of the hydrophilic coated stiffening obturator included in this turbo-ject PICC set.
Study NCT04393844 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: turbo-ject PICC set
Description: The turbo-ject PICC set, which will be used in this study, is the set for peripherally inserted central catheterization. In this study, we will see the difference according to the presence or absence of the hydrophilic coated stiffening obturator included in this turbo-ject PICC set.
Study NCT04332185 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vestibular socket therapy
Description: (VST) included the following steps. a-traumatic tooth extraction, the socket curetted and rinsed with normal saline thoroughly . One-cm long vestibular access incision was made using a 15c blade 3-4 mm apical to the mucogingival junction at the related socket. A subperiosteal tunnel was created connecting the socket orifice and the vestibular access incision using periotomes and micro periosteal elevators A flexible cortical membrane shield that is made of cortical bone of heterologous origin of 0.6 mm thickness was hydrated and then trimmed and introduced from the vestibular access incision reaching 1 mm below the socket orifice through the tunnel then stabilized using a micro screw to the alveolar bone apical to the base of the socket .
Study NCT01590966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: administration of Cimzia®
Description: Patients will be treated with prefilled syringes containing each 200 mg/ml Cimzia® every 2 weeks which will be administered subcutaneously (The first 3 injections, a dosage of 400mg Cimzia® subcutaneously will be administered).
Study NCT01590966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunoscintigraphy with radiolabeled Cimzia®.
Description: All 20 patients will undergo an immunoscintigraphy with radiolabeled Cimzia®. Certolizumab pegol (Cimzia®) is an engineered humanized monoclonal antibody Fab' fragment with specificity for human TNF-α, manufactured in E. coli. The antibody fragment is subsequently purified and conjugated with high molecular weight polyethylene glycol (PEG) (40kDa). Lyophilized Cimzia® will be conjugated with S-HYNIC (a bifunctional chelator). The conjugate will be radiolabeled with Tc-99m by adding 0.1 mg Tricine, 0.01 mg SnSO4 and 750 MBq Tc-99m pertechnetate. A dose of 750 MBq Tc-99m Cimzia® will be injected intravenously.
Study NCT04240847 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin incision
Description: Skin incision on medial or lateral to tibial tubercle
Study NCT01964456 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Joint perception task
Study NCT03169283 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cereal with B glucan
Description: A cereal high in viscous dietary fiber B glucan
Study NCT03169283 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cereal without B glucan
Description: Cereal without B glucan
Study NCT03560440 — intervention group
Intervention type: OTHER
Intervention: Plasma exposure vancomycin
Description: Investigation of plasma exposure of vancomycin.
Study NCT04240847 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Skin incision
Description: Skin incision on medial or lateral to tibial tubercle
Study NCT03607695 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait training
Description: Walking on a treadmill and receiving audio cues to improve gait
Study NCT02245373 — intervention group
Intervention type: DRUG
Intervention: Antidepressants
Study NCT02245373 — intervention group
Intervention type: OTHER
Intervention: Active Monitoring
Study NCT04627753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab, lenalidomide
Description: Maintenance for 2 years
Study NCT01124474 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: goal directed therapy
Description: Pulse contour waveform analysis derived stroke volume variation will be used to guide intraoperative fluid administration. Additional fluid boluses will be given to the patient when SVV>12%.
Study NCT04064710 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Vertebral Body Augmentation
Description: Use allograft tissue in patients with one or two level, thoracic or lumbar T6-L5, vertebral compression fractures.
Study NCT04064710 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Manual Surgical Instruments
Description: Lenoss Medical manual surgical access and cavity creation instruments will be used when implanting the allograft tissue.
Study NCT02285010 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo in capsule is prescribed to the patient 60 min prior to the surgery. Ringer Lactate Solution preload 15 mL/kg prior to surgery. Spinal anesthesia is done with 0.5% Heavy bupivacaine + morphine 0.2 mg total volume 3.0 - 3.6 mL. IV PCA Morphine is applied at PACU (bolus dose only 1 mg, lockout interval 5 min, 4 hr limit 35 mg). As soon as the patient is allowed to sip, paracetamol (500 mg) 1 tab PO every 6 hours is prescribed.
Study NCT02285010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Pregabalin (150 mg) one capsule is prescribed to the patient 60 min prior to the surgery.~Ringer Lactate Solution preload 15 mL/kg prior to surgery. Spinal anesthesia is done with 0.5% Heavy bupivacaine + morphine 0.2 mg total volume 3.0 - 3.6 mL. IV PCA Morphine is applied at PACU (bolus dose only 1 mg, lockout interval 5 min, 4 hr limit 35 mg). As soon as the patient is allowed to sip, paracetamol (500 mg) 1 tab PO every 6 hours is prescribed.
Study NCT01274897 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Novartis MenACWY-CRM
Description: All subjects had blood drawn at Day 1 and Day 29.
Study NCT01274897 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Description: All subjects had blood drawn at Day 1 and Day 29.
Study NCT03388970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin K 1
Description: Research group use Vitamin K1
Study NCT03388970 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Placebo group use normal saline
Study NCT00853905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triesence
Description: At end of standard glaucoma surgery and the anterior chamber is reformed with balanced salt solution or viscoelastic to an adequate intraocular pressure, 0.2cc of Triesence will be delivered into the anterior chamber through the previously created paracentesis wound.
Study NCT00853905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: balanced salt solution BSS
Description: At end of standard glaucoma surgery, the anterior chamber is reformed with balanced salt solution or viscoelastic to an adequate intraocular pressure.
Study NCT04079777 — intervention group
Intervention type: DRUG
Intervention: Clinical treatment
Description: Liquid Resuscitation, Anti-infection
Study NCT05828940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan Potassium
Description: oral tablet, over-encapsulated
Study NCT05828940 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablet, over-encapuslated
Study NCT01088412 — intervention group
Intervention type: DRUG
Intervention: Somatropin (recombinant deoxyribonucleic acid [rDNA] origin)
Description: Dose, frequency and duration at discretion of attending physician.
Study NCT04222621 — intervention group
Intervention type: OTHER
Intervention: Pregnant women without intervention
Description: Pregnant women with those exposures of interest determined in specific research based on the registry
Study NCT02024581 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10% East Indian sandalwood oil cream
Description: A topical oil/water emulsion cream containing 10% East Indian sandalwood oil (EISO)
Study NCT02024581 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cream
Description: A sandalwood-scented oil/water emulsion topical cream matching the appearance of the active comparator creams
Study NCT01240018 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: Parallel, randomized, controlled 2 arms study.
Study NCT01422447 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: regular intervention
Description: the subjects in the control group live in the used model
Study NCT01240018 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic
Description: Parallel, randomized, controlled 2 arms study.
Study NCT02786537 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOF/LDV (sofosbuvir/ledipasvir)
Description: Sofosbuvir/Ledipasvir (400/90 mg) for approximately 12 to 24 weeks (treatment duration and use of ribavirin is per discretion of HCV provider)
Study NCT01422447 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: community intervention
Description: in addition to regular intervention, those subjects in the intervention group will be given education intervention.
Study NCT01964456 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Joint perception task
Study NCT01964456 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Body Shape Questionnaire
Study NCT01964456 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Body Shape Questionnaire
Study NCT01964456 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Measure of the heart rate
Study NCT01660243 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nalfurafine hydrochloride(MT-9938) 2.5μg
Description: 2.5 μg (2capsules) once daily for 8 weeks
Study NCT01660243 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nalfurafine hydrochloride(MT-9938) 5μg
Description: 5 μg (2capsules) once daily for 8 weeks
Study NCT01660243 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nalfurafine hydrochloride(MT-9938) 10μg
Description: 10 μg (2capsules) once daily for 8 weeks
Study NCT01660243 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (2capsules) once daily for 8 weeks
Study NCT03521973 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Description: Radiation-attenuated, aseptic, purified, cryopreserved Plasmodium falciparum sporozoites (PfSPZ Vaccine)
Study NCT03521973 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 0.9% Sodium chloride
Study NCT02127463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MC-1101
Description: Topically, two times a day, morning and bedtime
Study NCT02127463 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MC-1101 Vehicle
Description: Topically, two times a day; morning and bedtime
Study NCT00951457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Study NCT00951457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Study NCT03541538 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Global manipulation
Description: The therapist positioned himself at the head of the stretcher and with one hand supported the side of the participant's face. With the other hand supported the opposite face of the same and then performed contralateral rotation of the cervical and a slight traction to the tissue barrier to perform the manipulation impulse of high speed and short amplitude in rotation. The procedure was carried out bilaterally.
Study NCT03541538 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Especific manipulation
Description: The therapist positioned himself at the head of the stretcher and with one hand kept the middle phalange of the second finger laterally on the articular processes of the C6-7 vertebrae. With the contralateral hand he supported the opposing face of the participant by performing a tilt up to the C6-7 segment and contralateral rotation up to the tissue barrier to carry out the impulse quickly and short. The procedure was carried out bilaterally.
Study NCT03415308 — intervention group
Intervention type: OTHER
Intervention: Focus Groups
Description: Investigators will use qualitative methods to gather data on the elements associated with the patient perception of implicit bias (e.g. communication, respect, patient-centeredness) to ensure that our selected outcomes reflect the breadth of patients' concerns.
Study NCT03415308 — intervention group
Intervention type: OTHER
Intervention: Cognitive Interviews
Description: To gather insights from stakeholders regarding how to best refine the design of our existing implicit bias intervention to ensure that we have addressed potential facilitators and barriers to uptake, use, and sustainability
Study NCT03415308 — intervention group
Intervention type: OTHER
Intervention: Pilot Testing of Implicit Bias Training
Description: Determine the feasibility of delivering the refined implicit bias reduction intervention and assessing patient centered outcomes by giving providers a refined implicit bias training.
Study NCT02097160 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin D fortified yogurt and cheese products
Study NCT02097160 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group 1
Study NCT02495207 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Piezosurgery
Description: This intervention is dependent on use of piezosurgery to conduct the required bone cuts to remove third molars.
Study NCT03480230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound 121564
Description: Compound 121564 10 mg/Kg administered over 60 minutes given intravenously every 2 weeks for 4 doses plus chemotherapy depending on tumor histology.
Study NCT00028587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT00028587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT00028587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT00028587 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies
Study NCT02911701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Study NCT01522547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pomalidomide
Description: Pomalidomide orally for 84 days daily in doses ranging from 0.5 mg to 4.0 mg
Study NCT02911701 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Study NCT02027493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reiferon R
Description: subcutaneous injection of 100 μg/m2
Study NCT02786537 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PrOD (ombitasvir/paritaprevir/ritonavir with dasabuvir) (Phase 1 only)
Description: Ombitasvir/paritaprevir/ritonavir (12.5/75/50mg) (2 tablets taken orally) and Dasabuvir (250 mg tablet) (1 tablet twice daily) with food for 12 to 24 weeks (treatment duration as per HCV provider)
Study NCT02027493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: 15 mg/kg daily on two divided doses
Study NCT00429962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravitreal ranibizumab
Description: intraocular injection
Study NCT00429962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravitreal ranibizumab & photodynamic therapy
Description: intraocular injection photodynamic treatment (LASER) after intravenous injection
Study NCT01604941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD602
Description: 50 mg/kg/day orally twice daily for 24 weeks
Study NCT02184936 — intervention group
Intervention type: OTHER
Intervention: standard of care
Study NCT03407287 — intervention group
Intervention type: PROCEDURE
Intervention: Peripheral Intravenous Analysis (PIVA)
Description: Non-invasive measurement of peripheral venous waveform analysis (PIVA) obtained by connecting a standard transducer (AD Instruments, Colorado Springs, Co) to a universal adaptor or stopcock on a peripheral IV
Study NCT03407287 — intervention group
Intervention type: PROCEDURE
Intervention: Standard of care invasive vascular monitoring
Description: Standard of care invasive monitoring in the intensive care settings with central venous catheters, pulmonary artery catheters, or trans-esophageal echocardiography for determining volume status.
Study NCT03407287 — intervention group
Intervention type: PROCEDURE
Intervention: Standard noninvasive vascular monitoring
Description: Standard noninvasive vascular monitoring of blood pressure, pulse rate, pulse oximetry and respiratory rate.
Study NCT01120340 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mesalamine
Description: mesalamine: 1.6 g/die for ten days/month until 24 months
Study NCT01120340 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 pills/day for ten days/month until 24 months
Study NCT01344590 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: Standard saline procedure will be utilized.
Study NCT01344590 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ethanol 70% pharmaceutical grade
Description: 70% pharmaceutical grade ethanol will be instilled in the line in a volume calculated to fill the lumen and the hub.
Study NCT04194801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase Ib: Fisogatinib (BLU-554) 400mg in combination with Sugemalimab (CS1001) 1200mg
Description: Phase Ib: participants received 400 mg Fisogatinib (BLU-554) once daily (QD), in combination with 1200mg fixed dose Sugemalimab (CS1001) once every 3 weeks (Q3W). Every 21 days (3 weeks) will be considered as one cycle.
Study NCT04194801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase Ib: Fisogatinib (BLU-554) 600mg in combination with Sugemalimab (CS1001) 1200mg
Description: Phase Ib: participants received 600 mg Fisogatinib (BLU-554) QD, in combination with 1200mg fixed dose Sugemalimab (CS1001) Q3W. Every 21 days (3 weeks) will be considered as one cycle.
Study NCT04194801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase II: Fisogatinib (BLU-554) 600mg in combination with Sugemalimab (CS1001) 1200mg
Description: Phase II: participants received 600 mg Fisogatinib (BLU-554) QD, in combination with 1200mg fixed dose Sugemalimab (CS1001) Q3W. Every 21 days (3 weeks) will be considered as one cycle.
Study NCT01793558 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Forced-air warming
Description: In the intervention group a forced-air cover (Level 1 Snuggle Warm Upper Body Blanket, Smiths Medicals) will be positioned over the upper body of the patients laying on the operating table just beginning after the spinal block.
Study NCT02518945 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Dapagliflozin or Farxiga is a SGLT-2 inhibitor
Study NCT02518945 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Study NCT02518945 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin
Study NCT02518945 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Victoza(Liraglutide) is a GLP-1 agent.
Study NCT02518945 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Liraglutide
Description: Victoza(Liraglutide) is a GLP-1 agent.
Study NCT02518945 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dapagliflozin placebo
Description: Dapagliflozin placebo looking similar to active drug Dapagliflozin in external appearance but not containing active ingredient dapagliflozin
Study NCT04056585 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound guided axillary plexus block
Description: Ultrasound guided axillary plexus block with 1.5% mepivacaine 30 ml
Study NCT04056585 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided axillary plexus block
Description: Ultrasound guided axillary plexus block with 1.5% mepivacaine 30 ml
Study NCT04056585 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression maneuver
Description: Following ultrasound guided axillary plexus block, the pneumatic compression maneuver of upper arm is composed of 6 repeated inflation-deflation periods; inflation with a pressure of 200 mmHg for 30 seconds and deflation for 10 seconds each.
Study NCT03740295 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coconut oil and epigallocatechin gallate
Description: 600 mg of epigallocatechin gallate (EGCG) and 60 ml of coconut oil (3600 mg of TGCM) per day, divided into two doses (one in the morning and one at noon)
Study NCT03740295 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose
Study NCT03307577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UHE-101 Cream
Description: Topical cream containing investigational drug at a concentration of 1%
Study NCT03307577 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: Topical cream containing no drug (i.e., placebo)